Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to 1.61%.

  • Integra Lifesciences Holdings' EBITDA Margin rose 28100.0% to 1.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 29.43%, marking a year-over-year decrease of 294300.0%. This contributed to the annual value of 1.76% for FY2024, which is 54700.0% down from last year.
  • Per Integra Lifesciences Holdings' latest filing, its EBITDA Margin stood at 1.61% for Q3 2025, which was up 28100.0% from 118.11% recorded in Q2 2025.
  • In the past 5 years, Integra Lifesciences Holdings' EBITDA Margin registered a high of 21.06% during Q1 2021, and its lowest value of 118.11% during Q2 2025.
  • Over the past 5 years, Integra Lifesciences Holdings' median EBITDA Margin value was 7.37% (recorded in 2021), while the average stood at 0.4%.
  • Per our database at Business Quant, Integra Lifesciences Holdings' EBITDA Margin surged by 264200bps in 2021 and then crashed by -1132100bps in 2025.
  • Quarter analysis of 5 years shows Integra Lifesciences Holdings' EBITDA Margin stood at 14.36% in 2021, then grew by 19bps to 17.04% in 2022, then crashed by -47bps to 9.08% in 2023, then dropped by -11bps to 8.05% in 2024, then plummeted by -120bps to 1.61% in 2025.
  • Its last three reported values are 1.61% in Q3 2025, 118.11% for Q2 2025, and 5.7% during Q1 2025.